Deals, Partnering

Merck inks domestic rights to Afluria from CSL

Posted on 29 September 2009

Tags: , ,

The six-year agreement with CSL Biotherapies, a division of CSL, calls for Merck to market Afluria in the United States, where it was approved by the Food and Drug Administration in 2007, starting next year. CSL will make the vaccine and maintain marketing and distribution rights in the rest of the world.

Print Friendly, PDF & Email

Leave a Reply